Your Article Summary
See Latest ArticlesLipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Robinson JG et al. – Ezetimibe/simvastatin (E/S) is more likely to result in lipid treatment endpoints than atorvastatin and was generally well tolerated at the compared doses.
Methods- Double-blind, randomized, 6-week study of lipid-lowering efficacy of E/S 10/20 mg vs atorvastatin 10 or 20 mg, and E/S 10/40 mg vs atorvastatin 40 mg
- Subjects: 1,128 pts with hypercholesterolemia and the metabolic syndrome
- Primary endpoint: percentage of change from baseline in low-density lipoprotein (LDL) cholesterol
- Additional endpoints: changes in other lipids, lipoprotein ratios, high-sensitivity C-reactive protein, and attainment of pre-specified lipid levels
- Significantly greater improvements in levels of LDL cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios with E/S vs atorvastatin at all dose comparisons
- Attainment of prespecified LDL cholesterol and non–high-density lipoprotein cholesterol levels significantly greater with E/S vs atorvastatin at all dose comparisons
- High-density lipoprotein cholesterol increases significantly greater with E/S 10/20 mg vs atorvastatin 10 mg and E/S 10/40 mg vs atorvastatin 40 mg
- Changes in triglycerides, very low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein similar for both treatments
- Low incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events, generally similar to those in previous studies of E/S and/or atorvastatin
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Internal and Emergency Medicine, 12/09/09
Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis
Atherosclerosis, 12/09/09
Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia
Atherosclerosis, 12/09/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC–FFCD 9710
Endocrine-Related Cancer, 12/09/09
A Randomized Controlled Trial of Oxycodone vs Placebo in Patients With PostHerpetic Neuralgia and Painful Diabetic Neuropathy Treated With Pregabalin
The Journal of Pain, 12/09/09
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Pituitary, 12/08/09